VAISHALI PHARMA LIMITED
VAISHALI · Defence · NSE
₹7
Current Market Price
Fair Value (DCF)
₹3
Discount to FV
-58.6%
Updated just now
YieldIQ Score
40/100
Piotroski F-Score
5/9
Economic Moat
None
Confidence
41%
ROE
1.3%
Debt/Equity
0.19
WACC
11.1%
Market Cap
₹95.24 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
4.9%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
1.6×
EBIT covers interest
Current Ratio
2.61×
Short-term liquidity
Asset Turnover
0.89×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.0%
3-year revenue growth
Revenue CAGR (5Y)
10.3%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹7.3
Bear case
Margin of Safety —
Implied upside -280.2%
Base case
Margin of Safety —
Implied upside -141.7%
Bull case
Margin of Safety —
Implied upside -101.7%
Ratio Trends
VAISHALI · last 4 annual periods
ROE
1.3%
ROCE
4.9%
Operating Margin
—
Debt / Equity
0.19×
PE
288.2×
EV / EBITDA
165.2×
Historical Financials
VAISHALI · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 NSE_XBRL | 2022 yfinance | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹53.8 Cr | ₹71.5 Cr | ₹63.8 Cr | ₹81.8 Cr | ₹97.9 Cr | +16.2% |
| EBITDA | — | ₹8.7 Cr | ₹11.6 Cr | ₹3.7 Cr | ₹3.8 Cr | -18.8% |
| EBIT | ₹4.0 Cr | — | ₹10.9 Cr | ₹2.7 Cr | — | -9.8% |
| PAT | ₹1.0 Cr | ₹4.0 Cr | ₹6.6 Cr | ₹0.7 Cr | ₹0.8 Cr | -6.0% |
| EPS (diluted) | ₹0.99 | — | ₹5.91 | ₹0.64 | — | -10.3% |
| CFO | ₹2.0 Cr | ₹1.3 Cr | ₹1.1 Cr | ₹0.8 Cr | ₹-18.0 Cr | — |
| CapEx | — | ₹-0.9 Cr | ₹-0.3 Cr | ₹-0.1 Cr | ₹-0.3 Cr | — |
| FCF | — | ₹0.5 Cr | ₹0.8 Cr | ₹0.7 Cr | ₹-18.3 Cr | — |
| Total Assets | — | ₹81.6 Cr | ₹78.9 Cr | ₹80.0 Cr | ₹110 Cr | +7.7% |
| Total Debt | — | ₹20.8 Cr | ₹14.7 Cr | ₹13.5 Cr | ₹12.3 Cr | -12.3% |
| Shareholders' Equity | — | ₹26.4 Cr | ₹40.5 Cr | ₹42.8 Cr | ₹64.9 Cr | +25.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
VAISHALI vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
PAR PAR | — | — | Pending | 13.5% | — |
BALPHARMA BAL PHARMA LTD. | +16.0%+19.1% upside | 55 | Below Fair Value | 7.6% | — |
KREBSBIO KREBSBIO | — | — | Pending | 10.4% | — |
ALPA ALPA | — | — | Pending | 8.1% | — |
VIVIMEDLAB VIVIMEDLAB | — | — | Pending | 90.9% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for VAISHALI in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. VAISHALI PHARMA LIMITED (VAISHALI.NS) trades at 7.30 vs a model fair value of 3.02, a gap of -58.6%. Piotroski F-score: 5/9. Moat label: ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of VAISHALI →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for VAISHALI →
Compare
Head-to-head with peers
Compare VAISHALI side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse VAISHALINow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.